I2 Therapeutics

i2O Therapeutics is a biopharmaceutical company developing next-generation GLP-1 combination therapies for obesity and cardio-renal-metabolic diseases. The company's pipeline spans multiple long-acting receptor agonist programs including two GLP-1 receptor agonists (RAs), two long-acting amylin dual agonist/co-agonist receptor agonists (DACRAs), a long-acting PYY receptor agonist, and a long-acting glucagon receptor agonist. By pairing GLP-1 backbones with complementary metabolic targets, i2O aims to deliver superior efficacy and tolerability versus single-agent GLP-1 therapies alone, addressing a major unmet need in the fast-growing obesity and metabolic disease treatment market.